Kidney cancer, Renal cell cancer
Results
Phase 3
This trial compared a new drug called dovitinib (pronounced dove-it-in-ib) with sorafenib in people with kidney cancer. The trial was for people with a type of kidney cancer called renal cell cancer that had come back after treatment (recurred). Dovitinib is also called TKI258.
Recruitment start: 1 March 2011
Recruitment end: 10 August 2012
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Paul Nathan
Novartis
NIHR Clinical Research Network: Cancer
Last reviewed: 25 May 2015
CRUK internal database number: 9114
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
